Mirvetuximab soravtansine shows 16.4-month OS in ovarian cancer, though poor ECOG status and toxicity significantly impact ...
There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results